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Background: Opioids not only exert an antinociceptive effect, but also modulate central N-methyl-D-aspartate 
(NMDA) receptors, resulting in hyperalgesia and acute opioid tolerance. This study was aimed to investigate the 
effect of the NMDA receptor antagonist, magnesium in preventing remifentanil-induced hyperalgesia.
Methods: For this study, 75 patients scheduled for robot-assisted laparoscopic prostatectomy were randomly 
allocated into three groups of patients whose incision sites were infiltrated: Group M, with 25% magnesium sulfate 
80 mg/kg; Group S, with the same volume of saline under remifentanil-based anesthesia, and Group D, with the 
same volume of saline under desflurane based anesthesia. All three groups were infiltrated into incision sites after 
pneumoperitoneum. Intraoperative evaluation included mean remifentanil dose, and postoperative evaluation 
included pain severity at time intervals of 30 min, 6, 12, 24 and 36 hours, time to first postoperative analgesic 
requirement, and analgesic dosage required during 24 hours.
Results: Mean remifentanil doses during the intraoperative periods in group M were significantly lower than those in 
group S (P < 0.001). The time to first postoperative analgesic requirement in postoperative period in groups M and D 
was significantly longer than that in group S (P < 0.001). Visual analog scale scores for pain in groups M and D were 
significantly lower than those in group S for 12 hours after operation.
Conclusions: A relatively high dose and continuous infusion of remifentanil were associated with opioid induced 
hyperalgesia. Wound infiltration with magnesium sulfate decreased opioid consumption and reduces opioid induced 
hyperalgesia. (Korean J Anesthesiol 2011; 61: 244-250)
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Introduction
The many advantages of robot-assisted laparoscopic pro-
statectomy (RALP) include: better visualization, more controlled 
finer movements of robotic arms allowing better dissection, less 
blood loss and improved continence and potency rates. RALP 
is a rapidly growing minimally invasive surgical approach. It is 
becoming a standard alternative to both open and laparoscopic 
surgical treatment for localized prostate cancer, especially in 
the United States [1]. However, postoperative pain may still be 
moderate to severe for some patients, and up to 80% of patients 
require opioid analgesia after laparoscopy [2]. Because the 
pain comprises several components, multimodal analgesic 
techniques are needed for effective postoperative analgesia [3].
Remifentanil is a short-acting opioid with predictable and 
rapid recovery that is relatively independent of the dose and the 
duration. Supplemental opioids are often given prophylactically 
to patients who are likely to experience postoperative pain 
[4]. This observation suggests that remifentanil may be asso-
ciated with opioid induced hyperalgesia. Magnesium is a 
physiological blocker of the NMDA receptor. Post-synaptic 
depolarization following nociceptive inputs decreases this 
ability to block calcium inflow through the receptor. Thus, by 
blocking the NMDA receptor throughout the perioperative 
period, magnesium might play a key role in postoperative pain, 
sensitization process and hyperalgesia [5]. Indeed, magnesium 
has been used as an effective adjuvant in postoperative pain 
management [6,7].
We hypothesized that intraoperative remifentanil administ-
ration results in acute opioid induced hyperalgesia (OIH) that 
is manifested by shortening of the time of first postoperative 
analgesic requirement, increased postoperative pain and 
opioid requirement. We therefore tested whether magnesium 
infiltration of incision sites in patients undergoing robot-
assisted laparoscopic prostatectomy under remifentanil based 
anesthesia reducing intraoperative opioid consumption and 
opioid induced hyperalgesia.
Materials and Methods
After obtaining approval from the Institutional Review Board 
and written informed consent, 75 ASA I-II patients undergoing 
RALP were enrolled in this study. Patients were excluded if they 
had major hepatic, renal and cardiovascular disease, asthma, 
chronic obstructive pulmonary disease, as well as known 
allergy to magnesium sulfate or other drugs, and treatment 
with calcium channel blocker, opioids and anticoagulant. 
Patients scheduled for the operation under remifentanil-
based anesthesia were randomly allocated into three groups 
that were infiltrated into their incision sites; group M with 25% 
magnesium sulfate 80 mg/kg, group S with the same volume of 
saline under remifentanil-based anesthesia and group D with 
same volume of saline under desflurane-based anesthesia after 
pneumoperitoneum.
All patients were premedicated with midazolam 2-3 mg 
before arrival in the operating room. The patients were placed 
routine monitors including pulse oximeter, automated cuffed 
blood pressure (BP), electrocardiogram (EKG), and end-tidal 
CO2 (ETCO2). Further, arterial and urinary catheter were placed 
accordingly as part of their routine management, and patients 
received lactated Ringer’s solution for crystalloid. To determine 
the pre and postoperative serum magnesium, albumin, 
and hematocrit levels, 4 ml of arterial blood samples were 
withdrawn from patients after induction of general anesthesia 
and at the end of surgery and analyzed immediately. 
Induction of anesthesia was commenced with a slow (30-
60 s) i.v. bolus dose of remifentanil 1 μg/kg followed by propofol 
1 mg/kg for group M and group S or, with propofol (2 mg/kg) in 
group D: tracheal intubation was facilitated with rocuronium 
(0.9 mg/kg) in all groups. After intubation of trachea, the 
patients are ventilated to normocapnia with 50% oxygen 
without nitrous oxide and, end-tidal desflurane concentration 
was maintained at 1 minimum alveolar concentration (MAC) 
according to age in groups M and S. The anesthesia level was 
monitored using the BIS method in all groups, as well as heart 
rate and blood pressure. The BIS electrodes were placed on 
the forehead and connected to BIS monitoring system (BIS XP, 
A-2000, Aspect Medical Systems, USA). BIS was maintained 
between the range of 40 to 60 during operation for three groups. 
Our criteria for possibly insufficient anesthesia were a heart 
rate that exceeded preinduction values by 15% and/or a systolic 
blood pressure that exceed baseline values by 20% for at least 5 
min.
Remifentanil was started at a rate of 0.3 μg/kg/min in group 
S and 0.1 μg/kg/min in group M and subsequently stepwise 
by 0.05 μg/kg/min increments if inadequate anesthesia was 
suspected. Group D patients received the same volume of saline 
in place of remifentanil, and the concentration of desflurane 
was titrated to prompted stepwise 1% reductions in desflurane 
concentration. The patients received 10 mg i.v. bolus doses of 
ephedrine, in case of persistent hypotension. If the heart rate 
decreased to less than 50 beats/min, 0.5 mg i.v. atropine bolus 
was administered.
The patients were placed in Trendelenburg position after 
anesthesia induction. All potential pressure points were pro-
tected with foam padding. The robot was parked between the 
abducted, slightly flexed legs supported by stirrups. Pneum-
operitoneum was maintained throughout the procedure (15 
mmHg). The camera port (12 mm), 2 robotic arm ports (8 mm) 
and 2 additional working ports (12 mm, for retraction, suction, 246 www.ekja.org
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and introduction and cutting of sutures) were carefully planned 
according to the geometry of the anatomic landmarks.
At the end of surgery, neuromuscular blockade was rever-
sed with pyridostigmine 0.2 mg/kg, glycopyrrolate 0.008 mg/
kg when the TOF ratio had returned to 25%. When BIS values 
reached 80 and spontaneous breathing was achieved, extu-
bation was performed. Remifentanil infusion was discontinued 
when the last surgical stitch was placed. Every patients were 
administered analgesics by patient-controlled analgesia (PCA) 
pump (Accufusor
Ⓡ WooYoung medical, Korea) containing mor-
phine (40 mg), ketorolac (180 mg), and ramo  setron (0.6 mg) in 
normal saline in a total volume of 100 ml. This device was set to 
deliver a basal infusion 2 ml/hr, a bolus dose of 0.5 ml with a 15 
min lockout time. Pain scores at movement were documented 
using the 100 mm linear visual analog scale (VAS) which is 
a straight line with the left end of the line representing no 
pain and the right end of the line representing the worst pain. 
Patients are asked to mark on the line where they think their 
pain is. Intraoperative evaluation included time weighted mean 
remifentanil dose, the age-adjusted desflurane concentration, 
and postoperative evaluation included degree of pain severity at 
30 min, and 6, 12, 24 and 36 hours, the time to first postoperative 
analgesic (pethidine or ketorolac) requirement, and analgesic 
dose required during the first 24 hours. Side effects including 
hypotension, bradycardia, nausea, and shivering were also 
recorded. All patients were monitored in the postoperative 
recovery room for the first 24 hours. 
Postoperative monitoring included noninvasive blood 
pressure, heart rate, and pulse oximetry. Nausea was treated 
with i.v. metoclopromide (10 mg), and postoperative shivering 
was treated with a forced air warming blanket. A trained 
anesthesiologist who was not involved in this study assessed 
pain, and analgesic consumption. An i.v. dose of pethidine 25 
mg if patients reported VAS ≥ 50 or i.v. dose of ketorolac 30 mg if 
VAS < 50 were administered during recovery for 24 hours.
A preliminary investigation showed that hypothesized 
means of time to first postoperative analgesic requirement in 
postoperative period in group M, group D and group S were 45.3 
min, 43.2 min and 36.1 min respectively, and standard deviation 
of subjects was 10.3. Sample size of 24 patients per group is 
needed to demonstrate a significant difference, with power 
of 80% and an α-coefficient of 0.05. The results are presented 
as mean ± SD or the number of patients. Comparisons of age, 
body weight, operation time, vol% of desflurane, the time to first 
postoperative analgesic requirement, fluid administered, VAS 
scores for pain and analgesics administered among groups were 
conducted by using One-way ANOVA. Time-weighted mean 
remifentanil dose between Groups M and S was conducted by 
using an unpaired t-test. Chi-Square test was used to analyze 
categorical data such as hypotension, bradycardia, nausea, 
shivering and dysrhythmia. P < 0.05 was considered the mini-
mum level of statistical significance.
Results
The three groups were comparable with respect to age, 
height, weight, fluid administered, hypotension, bradycardia, 
nausea, and dysrhythmia. Desflurane concentration admini-
stered was significantly lower in group M than in group D. 
Shivering in group M was significantly lower than that in other 
groups (Table 1).
Time weighted mean remifentanil dose in group S was 
significantly greater than that of group M. Total rocuronium 
consumption of group M was significantly lower than that 
in group D and group S. Time to first operative analgesic 
requirement of group S was significantly shortest than those of 
Table 1. Demographic and Clinical Variances
Group M
(n = 25)
Group D
(n = 25)
Group S
(n = 25)
P value
Age (yrs)
Weight (kg)
Height (cm)
Operation time (min)
Vol.% desflurane
Adiminstered fluid (ml)
Hypotension
Bradycardia
Nausea
Shivering
Dysrhythmia
62.8 ± 3.6
63.2 ± 4.5
166.9 ± 3.0
301.0 ± 18.4
5.40 ± 0.76*
2,676.0 ± 314.0
3
4
5
1
†
1
63.1 ± 4.0
61.8 ± 5.5
166.1 ± 3.4
299.4 ± 14.1
6.12 ± 1.01
2,532.4 ± 332.6
3
2
1
7
0
64.0 ± 3.8
65.1 ± 5.9
165.9 ± 3.3
296.8 ± 17.4
5.88 ± 0.92
2,508.0 ± 340.2
5
6
2
9
1
>0.05
>0.05
>0.05
>0.05
 0.013
>0.05
>0.05
>0.05
>0.05
 0.017
>0.05
Values are mean ± SD. Group M: 25% magnesium sulfate (80 mg/kg) under remifentanil-based anesthesia. Group S: same volume of saline 
under remifentanil-based anesthesia. Group D: same volume of saline under desflurane-based anesthesia. *P < 0.05 versus group D. 
†P < 0.05 
versus other groups. 247 www.ekja.org
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group M and group D, but there was no significant difference 
between groups M and D. The pethidine dose administered 
for 24 hours in group S was significantly greater than those 
in groups M and D, but there was no significant difference 
between groups M and D (Table 2). Postoperative cumulative 
injected volume of the PCA pump in group S was significantly 
greater than those in groups M and D, but there was no 
significant difference between groups M and D (Table 3).
There were no significant differences in preoperative and 
postoperative total magnesium and albumin level in all groups 
(Fig. 1 and 2). Postoperative hematocrit was significantly de-
creased to preoperative hematocrit in all groups (Fig. 3).
VAS scores for pain were significantly higher in group S 
than in group M for 24 hours and in group D for 12 hours after 
operation, but there was no significant difference between 
groups M and D (Fig. 4). 
Discussion
The results of this study demonstrated that there was no 
Table 2. Assessment of Analgesics Given during the Perioperative Period
Group M
(n = 25)
Group D
(n = 25)
Group S
(n = 25)
P value
Time weighted mean remifentanil dose (µg/kg/min)
Total rocuronium consumption (mg/kg/h)
Time to first postoperative analgesic requirement (min)
Analgesic type received
    Pethidine (mg)
    Ketorolac (mg)
0.11 ± 0.03
0.55 ± 0.03
†
63.6 ± 6.8
32.0 ± 11.5
46.8 ± 15.2
0
0.68 ± 0.05
61.4 ± 5.3
34.0 ± 12.2
49.2 ± 14.7
0.30 ± 0.07*
0.67 ± 0.06
34.0 ± 8.7
‡
48.0± 12.3
‡
45.6 ± 15.3
<0.01
<0.01
<0.01
<0.01
Values are mean ± SD. Group M: 25% magnesium sulfate (80 mg/kg) under remifentanil-based anesthesia. Group S: same volume of saline 
under remifentanil-based anesthesia. Group D: same volume of saline under desflurane-based anesthesia. *P < 0.05 versus group M. 
†P < 0.05 
versus the other groups. 
‡P < 0.05 versus the other groups. 
Table 3. Postoperative Cumulative Injected Volume through Patient-Controlled Analgesia (PCA) Pump (ml) 
Group M
(n = 25)
Group D
(n = 25)
Group S
(n = 25)
P value
1 hr
6 hr
12 hr
24 hr
36 hr
3.04 ± 0.54
16.56 ± 0.91
36.66 ± 1.48
62.50 ± 1.49
86.84 ± 1.38
3.24 ± 0.44
17.08 ± 1.03
37.38 ± 1.33
63.52 ± 1.71
87.72 ± 1.49
3.64 ± 0.45*
18.44 ± 1.40*
39.56 ± 1.78*
64.76 ± 1.82*
88.88 ± 1.66*
<0.01
<0.01
<0.01
<0.01
<0.01
Values are mean ± SD. Group M: 25% magnesium sulfate (80 mg/kg) with remifentanil. Group S: same volume of saline with remifentanil. 
Group D: same volume of saline with desflurane.  *P < 0.05 versus the other groups.
Fig. 1. Preoperative and postoperative serum magnesium. Values 
are mean ± SD. Group M: 25% magnesium sulfate (80 mg/kg) with 
remifentanil. Group S: same volume of saline with remifentanil. 
Group D: same volume of saline with desflurane. There were no 
significant differences among groups.
Fig. 2. Preoperative and postoperative serum albumin. Values are 
mean ± SD. Group M: 25% magnesium sulfate (80 mg/kg) with 
remifentanil. Group S: same volume of saline with remifentanil. 
Group D: same volume of saline with desflurane. There were no 
significant differences among groups.248 www.ekja.org
Vol. 61, No. 3, September 2011 Magnesium and hyperalgesia
significant difference in desflurane concentration between 
groups S and D, and group S who received a continuous intra-
operative remifentanil compared with group D who received 
saline resulted in acute opioid induced hyperalgesia (OIH). OIH 
in this study was manifested by the shortening of time of first 
postoperative analgesic requirement, increased postoperative 
pain, and opioid requirement. Group M reduced OIH which 
was shown in group S.
OIH is most broadly defined as a state of nociceptive sensiti-
zation caused by exposure to opioid. The state is characterized 
by a paradoxical response where one actually become more 
sensitive to certain painful stimuli. In clinical setting, OIH 
may represent one of many reasons for declining levels of 
analgesia while receiving opioids or worsening pain syndrome. 
This phenomenon is thought to result from neuroplastic 
changes in the central nervous system or peripheral nervous 
system leading to sensitization of pronociceptive pathway 
[8]. Conflicting results have been published concerning the 
effect of intraoperative remifentanil dose on postoperative 
pain sensitivity. Two prospective controlled clinical studies 
have reported increased postoperative pain despite increased 
postoperative opioid [9,10]. A study by Joly et al. [11] directly 
measured the development of secondary wound hyperalgesia 
after acute intraoperative opioid exposure. The authors found 
that high-dose intraoperative exposure to the potent, ultra 
short-acting μ-opioid agonist remifentanil increased peri-
incisional wound allodynia and hyperalgesia measured by von 
Frey hairs compared with low-dose intraoperative remifentanil 
in patients undergoing major abdominal surgery. These findings 
are contrasted by other studies that did not show an effect of 
intraoperative opioid dose on postoperative pain sensitivity. 
Cortínez et al. [12] did not find increased pain or postoperative 
opioid consumption after high-dose intraoperative remifentanil 
exposure in patients undergoing elective gynecologic surgery. 
Additionally, Lee et al. [13] also did not see a significant diffe-
rence in postoperative pain or opioid consumption in patients 
who received intraoperative remifentanil compared with 70% 
nitrous oxide after colorectal surgery. Opioids not only exert 
an antinociceptive effect but also modulate central NMDA 
receptors, resulting in hyperalgesia and acute opioid tolerance. 
NMDA receptor antagonists such as ketamine or magnesium, 
have been demonstrated to increase the analgesic effects of 
opioids, probably by limiting these NMDA-mediated facilitating 
processes [14]. 
Magnesium can then lead to a decrease in postoperative 
pain and analgesic consumption, and has been used as an 
effective adjuvant in postoperative pain management [5-7].
It has been reported that volatile anesthetics including des-
flurane block the NMDA receptor [15,16]. However, Hollmann 
et al. [15] reported that desflurane inhibits control response of 
NMDA receptor to glutamate only by 20% at 0.5 MAC and 40% at 
1 MAC. This results support that a small difference in desflurane 
concentration does not explain the exaggerated hyperalgesia in 
group S which received a large dose of remifentanil.
The development of hypomagnesemia has been reported in 
60-70% of postoperative patients [17,18]. There is a evidence 
that the response of the NMDA receptor is greatly enhanced 
by reducing the extracellular magnesium concentration below 
physiologic levels [19]. However, this study showed that there 
were no significant differences in preoperative and post-
operative total magnesium level among groups, although group 
S and group D showed reduction of magnesium in postoperative 
Fig. 3. Preoperative and postoperative hematocrit. Values are mean ± 
SD. Group M: 25% magnesium sulfate (80 mg/kg) with remifentanil. 
Group S: same volume of saline with remifentanil. Group D: same 
volume of saline with desflurane. *P < 0.05 versus preoperative 
hematocrit in each group.
Fig. 4. Sequential changes of VAS pain scores during movement 
in three groups after operation. VAS: visual analog scale. Values 
are mean ± SD. Group M: 25% magnesium sulfate (80 mg/kg) with 
remifentanil. Group S: same volume of saline withremifentanil. 
Group D: same volume of saline with desflurane. *P < 0.05 versus 
group M and group D. 
†P < 0.05 versus group M.249 www.ekja.org
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period. This result suggests that magnesium sulfate does not 
act through its systemic action [20]. The mechanism of peri-
pherally administered magnesium sulfate remain unclear. 
Some studies identified perial NMDA receptor in the skin and 
muscles [21,22]. Tauzin-Fin et al. [23] recently reported that 
co-administration of magnesium sulfate with ropivacaine for 
postoperative infiltration analgesia after radical retropubic 
prostatectomy procedures provided a significant reduction in 
opioid requirement. Magnesium provides anesthetic, analgesic, 
anti-shivering and muscle-relaxant effects.
This study showed that time to first operative analgesic 
require  ment, pethidine dose administered, VAS scores for 
pain, postoperative cumulative injected volume of PCA 
pump, shivering and rocuronium consumption in group M 
were significantly better compared with those in group S, 
but pain-related clinical variances were no significant when 
compared with group D. Based on these findings, we suggest 
that magnesium itself do not produces antinociceptive 
effects but prevents opioid induced hyperalgesia. In clinical 
practice, magnesium’s beneficial effect on shivering is of minor 
importance compared with the efficacy that was reported with 
meperidine or clonidine [24,25].
In conclusion, we confirmed our hypothesis that intraopera-
tive remifentanil administration results in acute OIH that is 
manifested by shortening of the time of first postoperative 
analgesic requirement, increased postoperative pain and 
opioid requirement in group S under remifentanil based 
anesthesia compared with group D under desflurane based 
anesthesia. There were no advantages in group S (combined 
desflurane and remifentanil) over group D (desflurane only) 
as far as pain, although remifentanil-based anesthesia has 
been known to have an advantage in a predictable and rapid 
recovery. Magnesium infiltration of incision sites in patients 
undergoing robotic-assisted laparoscopic prostatectomy under 
remifentanil-based anesthesia reduces intraoperative opioid 
consumption and opioid induced hyperalgesia. Further studies 
are required to obtain more informations about safety and to 
determine whether doses of magnesium sulfate can provide 
postoperative analgesic benefits.
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